Is Cjjd a good buy

**China Jo-Jo Drugstores (CJJD) does not appear to be a good buy at this time**, based on the following analysis: 1. **Financial Health Concerns**: - The company has a negative free cash flow of $201,455.84, which indicates that it is not generating enough cash to cover its expenses. - The debt-to-equity ratio stands at 440.36%, suggesting that the company has a high level of debt relative to its equity, which can be risky. 2. **Valuation Metrics**: - The price-to-earnings (P/E) ratio is -0.8, which is negative and suggests that the company is not profitable. - The price-to-book (P/B) ratio is 0.9, and the price-to-sales (P/S) ratio is 0.11, both of which are relatively low, indicating that the stock may be overvalued. - The price-to-cash flow (P/CF) ratio is not available, which limits the ability to compare this metric. |Ticker|Name|Price to Book Ratio|P/S|P/E(TTM)|Date|code|market_code| |---|---|---|---|---|---|---|---| |CJJD.O|China Jo-Jo Drugstores||0.10924370210662354|-0.799679|20240729|CJJD|186| |CJJD.O|China Jo-Jo Drugstores|0.8975|||20240730|CJJD|186| 3. **Market Performance and Outlook**: - The company has a history of negative earnings over the last 12 months, which is a red flag for investors. - The competitive environment in the retail pharmacy sector is intensifying, with the entry of Amazon Pharmacy, which could impact CJJD's market share and profitability. - The long-term forecast for the stock price is positive, with expected increases up to 2025, but these forecasts are based on historical performance and may not accurately reflect future market conditions. 4. **Investor Considerations**: - The company has recently sold shares in a registered direct offering, which could dilute existing shares and impact the stock price. - The stock has a high beta of 0.56, indicating that it is more volatile than the market, which can lead to higher risk and potential losses. In conclusion, while there is a long-term forecast for stock price appreciation, the current financial health of the company and the competitive landscape suggest that CJJD is not a good buy at this time. Investors should consider the risks associated with the company's financials and market dynamics before making an investment decision.